Name | Type | Description | Interventions |
---|
Part 1: Belantamab Mafodotin + VRd/Rd (Cohort 1) | Experimental | Participants will receive 1.9 milligram (mg)/kilogram (kg) single dose of belantamab mafodotin intravenously (IV) on Day 1 every 21-day cycle for the first 8 (induction) cycle in combination with VRd, and cycle 9 (28-day maintenance cycle) onward in combination with Rd (Revlimid [lenalidomide], dexamethasone). | - Belantamab mafodotin
- Bortezomib
- Lenalidomide
- Dexamethasone
|
Part 1: Belantamab Mafodotin + VRd/Rd (Cohort 2a) | Experimental | Participants will receive belantamab mafodotin 1.25 mg/kg on Day 1 and Day 8 through IV of every 21-day cycle for the first 8 (induction) cycles in combination with VRd, and cycle 9 (28-day maintenance cycle) onward in combination with Rd. | - Belantamab mafodotin
- Bortezomib
- Lenalidomide
- Dexamethasone
|
Part 1: Belantamab Mafodotin + VRd/Rd (Cohort 2b) | Experimental | Participants will receive 2.5 mg/kg on single dose of belantamab mafodotin through IV on Day 1, every 21-day cycle for the first 8 (induction) cycles in combination with VRd, and cycle 9 (28-day maintenance cycle) onward in combination with Rd. | - Belantamab mafodotin
- Bortezomib
- Lenalidomide
- Dexamethasone
|
Part 1: Belantamab Mafodotin + VRd/Rd (Cohort 3) | Experimental | Participants will receive belantamab mafodotin 1.7 mg/kg on Day 1 and Day 8 through IV, every 21-day cycle for the first 8 (induction) cycles in combination with VRd, and cycle 9 (28-day maintenance cycle) onward in combination with Rd. | - Belantamab mafodotin
- Bortezomib
- Lenalidomide
- Dexamethasone
|
Part 1: Belantamab Mafodotin + VRd/Rd (Cohort 4) | Experimental | Participants will receive 3.4 mg/kg single dose of belantamab mafodotin through IV on Day 1, every 21-day cycle for the first 8 (induction) cycles in combination with VRd, and cycle 9 (28-day maintenance cycle) onward in combination with Rd. | - Belantamab mafodotin
- Bortezomib
- Lenalidomide
- Dexamethasone
|
Part 2: Belantamab Mafodotin + VRd | Experimental | Participants will receive selected dose of belantamab mafodotin RP3D plus VRd (1.3 milligrams per square meter [mg/m^2] of bortezomib subcutaneously [SC] on Days 1, 4, 8, and 11, lenalidomide 25 mg on Days 1-14, and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 orally) of every 21-day cycle for the 8 induction cycles, and with Rd (lenalidomide 25 mg on Days 1-21 and dexamethasone 40 mg on Days 1, 8, 15, 22) of each 28-day cycle until PD (progressive disease) or unacceptable toxicity. | - Belantamab mafodotin
- Bortezomib
- Lenalidomide
- Dexamethasone
|
Part 2: VRd alone | Experimental | Participants will receive VRd (1.3 mg/m^2 of bortezomib SC on Days 1, 4, 8, and 11, lenalidomide 25 mg on Days 1-14, and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 orally) of every 21-day cycle for the 8 induction cycles, and with Rd (lenalidomide 25 mg on Days 1-21 and dexamethasone on 40 mg on Days 1, 8, 15, 22) of each 28-day cycle until PD or unacceptable toxicity | - Bortezomib
- Lenalidomide
- Dexamethasone
|